Outcomes following venetoclax-based treatment in therapy-related myeloid neoplasms
- Author(s)
- Shah, MV; Chhetri, R; Dholakia, R; Kok, CH; Gangat, N; Alkhateeb, HB; Al-Kali, A; Patnaik, MM; Baranwal, A; Greipp, PT; He, R; Begna, KH; Tiong, IS; Wei, AH; Hiwase, D;
- Details
- Publication Year 2022-08,Volume 97,Issue #8,Page 1013-1022
- Journal Title
- American Journal of Hematology
- Publication Type
- Research article
- Abstract
- Therapy-related myeloid neoplasms (t-MN) are aggressive malignancies in need of effective therapies. The BCL-2 inhibitor venetoclax represents a paradigm shift in the treatment of acute myeloid leukemia. However, the effectiveness of venetoclax has not been studied in a large cohort of t-MN. We retrospectively analyzed 378 t-MN patients, of which 96 (25.4%, 47 therapy-related acute myeloid leukemia, 1 therapy-related chronic myelomonocytic leukemia, 48 therapy-related myelodysplastic syndrome) received venetoclax. Median interval from t-MN to venetoclax initiation was 2.9 (Interquartile range [IQR] 0.7-12) months, and patients received a median of 3 (IQR 1-4) cycles. The composite complete remission (CRc) rate, median progression-free survival (PFS), and overall survival (OS) were 39.1%, 4.9 months, and 7 months, respectively. The upfront use of venetoclax and achieving CRc were associated with improved survival, whereas the presence of Chromosome 7 abnormalities was associated with an inferior survival. Neither the TP53-status nor the percent bone marrow blast predicted the likelihood of CRc or survival. Paired genetic analysis performed at venetoclax initiation and failure did not show the evidence of the selection of the TP53-mutated clone. In a propensity-matched analysis, the use of venetoclax-based regimen as the first-line therapy was associated with a superior survival compared to hypomethylating agent (HMA)-based first-line therapy (9.4 vs. 6.1 months, p = .01). We conclude that the upfront use of venetoclax with HMA improved survival, though PFS and OS remain poor. As the phenotype at diagnosis or the percent blasts did not predict outcomes, venetoclax should be studied in all t-MN phenotypes.
- Keywords
- Antineoplastic Combined Chemotherapy Protocols/adverse effects; Bridged Bicyclo Compounds, Heterocyclic/adverse effects; Humans; *Leukemia, Myeloid, Acute/drug therapy/genetics; *Neoplasms, Second Primary; Retrospective Studies; Sulfonamides/adverse effects
- Department(s)
- Haematology
- PubMed ID
- 35560061
- Publisher's Version
- https://doi.org/10.1002/ajh.26589
- Open Access at Publisher's Site
https://doi.org/10.1002/ajh.26589- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2025-04-04 12:33:48
Last Modified: 2025-04-04 12:35:17